BCAX (Bicara Therapeutics) Total Tax Payable : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Total Tax Payable?

Bicara Therapeutics's Total Tax Payable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Bicara Therapeutics Total Tax Payable Historical Data

The historical data trend for Bicara Therapeutics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Total Tax Payable Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Total Tax Payable

Bicara Therapeutics Quarterly Data
	Dec22	Sep23	Dec23	Jun24	Sep24	Dec24
Total Tax Payable	Get a 7-Day Free Trial			-	-	-	-	-

Bicara Therapeutics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Bicara Therapeutics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Total Tax Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

https://www.bicara.com

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.